Targeting PDGF Signaling in Cervical Cancer
Author Information
Author(s): Rakesh K Jain, Johanna Lahdenranta, Dai Fukumura
Primary Institution: Massachusetts General Hospital and Harvard Medical School
Hypothesis
Can targeting PDGF signaling in carcinoma-associated fibroblasts slow the progression of cervical cancer?
Conclusion
Targeting PDGF signaling in carcinoma-associated fibroblasts can slow cervical cancer progression and impair invasive growth.
Supporting Evidence
- Targeting PDGF signaling can impair the growth of invasive carcinomas.
- Blocking PDGF receptors in carcinoma-associated fibroblasts can reduce pro-angiogenic factors.
- Imatinib, a drug that targets PDGF signaling, is suggested for clinical testing in cervical cancer.
Takeaway
This study shows that a specific signaling pathway in cancer cells can be blocked to help slow down cervical cancer growth.
Methodology
The study used a mouse model of cervical carcinogenesis to investigate the effects of blocking PDGF receptors in carcinoma-associated fibroblasts.
Potential Biases
Potential conflicts of interest due to funding and consulting relationships of the authors.
Limitations
The study does not address the potential adverse effects of targeting PDGF signaling on normal tissues and the variability of fibroblast phenotypes across different organs.
Participant Demographics
Mouse model used; no human participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website